Highlights

For 17p, I think it’s pretty easy, I pretty much start everyone on a BTK inhibitor. For individuals who don’t have 17p, who need treatment, I think that right now it’s about – I think it’s pretty quickly changing, but right now it’s probably half the folks will get chemo, like BR, and then the other half will get like a BTK inhibitor. Like, I don’t really give BCL2 inhibitors to anybody up front. I would say that in, like, five years my guess is that almost everyone is going to be on a BTK inhibitor.

Following ibrutinib I would say there’s a pretty healthy proportion of patients who don’t progress, they just don’t tolerate it. So, they don’t tolerate the therapy, and so switching from ibrutinib to acalabrutinib is a pretty easy thing to do. So, I would say that for 17p people who just need a change in therapy because they have progressed, then almost 100% of people go on venetoclax. I would say that it’s probably 50:50 – those that change because of intolerance and those that change because of progression.